Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy
about
Optimizing treatments for lymphangioleiomyomatosisManagement of lymphangioleiomyomatosisClinical features, epidemiology, and therapy of lymphangioleiomyomatosisUterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion.Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis.Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.Lymphangioleiomyomatosis - a wolf in sheep's clothing.Lymphangioleiomyomatosis: current and future.Simultaneous activation and inhibition of autophagy sensitizes cancer cells to chemotherapy.SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Lymphangioleiomyomatosis: New Treatment Perspectives.AMP-dependent kinase and autophagic flux are involved in aldehyde dehydrogenase-2-induced protection against cardiac toxicity of ethanolmTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholismImpaired autophagosome clearance contributes to neuronal death in a piglet model of neonatal hypoxic-ischemic encephalopathy.Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation.Modulation of mitochondrial function and autophagy mediates carnosine neuroprotection against ischemic brain damage.Emerging Roles for VEGF-D in Human Disease.
P2860
Q26865250-2DF90767-CF09-4CFF-885B-4AC8EE905138Q28084725-6D0AFEF1-FFD7-44BE-991D-6E475CC8BECDQ28084975-C9431AA3-1EAA-4AEF-84AD-64D94031F65DQ30411083-11E3286B-4BEA-4905-9550-47E8436828D9Q34471857-43F764F8-A240-48F7-A1C6-D9824E9B7BACQ35985429-A2A2CE07-2C61-4A78-ACF6-1C0C5FB8DDD0Q36232850-D26E579E-25EC-4D6C-A903-8E3FC9EBD98CQ36357766-59603754-8973-4A46-BE39-907183EA80EBQ36542254-38E3D25A-2D2E-4F5C-8174-A79311950FCFQ37628979-13EA5308-E2D7-48D5-B605-EFA574539022Q37691961-63CA24FC-16E8-469E-AD2E-C3FF785583BFQ37721031-21107D52-719C-466A-A43D-B72B64C1F732Q37937344-01F9FE3E-7059-478A-8571-3C088E9D5615Q38484497-878DCC57-7544-42E3-8CD6-CAAF2EBA5F9AQ38642240-5C81BF4A-02FC-4CE6-905C-08493ED69A7FQ38840550-CEC90F7A-650F-4738-8133-052091F26DEDQ41335427-20F79F8D-1B97-4B80-9E77-A92275FAA7A6Q41365464-5A797B18-07BA-49EB-8612-268629536E1EQ41827290-20FB6F8F-C5FA-491B-81FA-B4560211AFE2Q47233157-31DCCE0F-FC59-42ED-A563-C9586498BC85
P2860
Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@ast
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@en
type
label
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@ast
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@en
prefLabel
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@ast
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@en
P2093
P2860
P1476
Mammalian target of rapamycin ...... mphangioleiomyomatosis therapy
@en
P2093
Andrey A Parkhitko
Elizabeth Petri Henske
P2860
P356
10.1513/PATS.200909-104JS
P577
2010-02-01T00:00:00Z